Loading...
•
Dec 31, 2019
Nevro Q4 2019 Earnings Report
Nevro's Q4 2019 earnings report was released, showcasing revenue growth and strategic advancements.
Key Takeaways
Nevro Corp. reported a 6% increase in worldwide revenue for Q4 2019, reaching $114.4 million, with U.S. revenue up 7% to $97.9 million. The company launched Senza Omnia commercially in the U.S. and presented positive data from its Senza-PDN study.
Worldwide revenue increased by 6% year-over-year, reaching $114.4 million.
U.S. revenue grew by 7% compared to the prior year period, totaling $97.9 million.
U.S. patient trials and permanent implants grew by 17% and 20%, respectively.
Senza Omnia SCS System was commercially launched in the U.S.
Nevro
Nevro
Nevro Revenue by Geographic Location
Revenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Nevro reiterated its full year 2020 worldwide revenue to be in the range of $435 to $440 million. Gross margin is expected to be in the range of 69% to 70% and operating expenses are expected to be approximately $355 million, including litigation expenses. Adjusted EBITDA guidance of positive $3.0 to $10.0 million for the full year 2020.
Revenue & Expenses
Visualization of income flow from segment revenue to net income